Syndax Pharmaceuticals, Inc. (SNDX)

Market Cap	1.77B
Revenue (ttm)	n/a
Net Income (ttm)	-209.36M
Shares Out	84.97M
EPS (ttm)	-2.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,123
Open	20.59
Previous Close	20.57
Day's Range	20.48 - 20.99
52-Week Range	11.22 - 25.34
Beta	0.98
Analysts	Strong Buy
Price Target	35.00 (+68.43%)
Earnings Date	May 10, 2024

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 3, 2016
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: SNDX

Analyst Forecast

According to 12 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is $35.0, which is an increase of 68.43% from the latest price.

Price Target

$35.0

(68.43% upside)

Analyst Consensus: Strong Buy